DK1912991T3 - Xanthinderivater som selektive HM74A-Agonister - Google Patents

Xanthinderivater som selektive HM74A-Agonister

Info

Publication number: DK1912991T3
Authority: DK; Denmark
Prior art keywords: xanthine derivatives; hm74a agonists; selective; selective hm74a; agonists
Prior art date: 2005-08-10

Application number

DK06763016.0T

Other languages

English (en)

Inventor

Andrew Mcmurtrie Mason

Ivan Leo Pinto

Richard Jonathan Daniel Hatley

Original Assignee

Glaxosmithkline Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-10

Filing date

2006-08-08

Publication date

2011-02-21

2005-08-10 Priority claimed from GB0516464A external-priority patent/GB0516464D0/en

2006-04-19 Priority claimed from GB0607736A external-priority patent/GB0607736D0/en

2006-07-21 Priority claimed from GB0614569A external-priority patent/GB0614569D0/en

2006-08-08 Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc

2011-02-21 Application granted granted Critical

2011-02-21 Publication of DK1912991T3 publication Critical patent/DK1912991T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Obesity (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK06763016.0T 2005-08-10 2006-08-08 Xanthinderivater som selektive HM74A-Agonister DK1912991T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB0516464A GB0516464D0 (en)	2005-08-10	2005-08-10	Novel compounds
GB0607736A GB0607736D0 (en)	2006-04-19	2006-04-19	Novel compounds
GB0614569A GB0614569D0 (en)	2006-07-21	2006-07-21	Novel compounds
PCT/EP2006/007865 WO2007017261A1 (en)	2005-08-10	2006-08-08	Xanthine derivatives as selective hm74a agonists

Publications (1)

Publication Number	Publication Date
DK1912991T3 true DK1912991T3 (da)	2011-02-21

Family

ID=37189397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK06763016.0T DK1912991T3 (da)	2005-08-10	2006-08-08	Xanthinderivater som selektive HM74A-Agonister

Country Status (28)

Country	Link
US (3)	US20100179128A1 (da)
EP (3)	EP1912992A1 (da)
JP (2)	JP5112316B2 (da)
KR (2)	KR20080034993A (da)
AR (1)	AR055369A1 (da)
AT (1)	ATE487719T1 (da)
AU (2)	AU2006278215A1 (da)
BR (2)	BRPI0615145A2 (da)
CA (2)	CA2626723A1 (da)
CR (2)	CR9748A (da)
CY (1)	CY1111757T1 (da)
DE (1)	DE602006018151D1 (da)
DK (1)	DK1912991T3 (da)
EA (2)	EA014556B1 (da)
ES (1)	ES2401128T3 (da)
HR (1)	HRP20100725T1 (da)
IL (2)	IL189083A0 (da)
MA (2)	MA29692B1 (da)
MX (2)	MX2008001931A (da)
MY (1)	MY142067A (da)
NO (2)	NO20081212L (da)
NZ (1)	NZ565494A (da)
PE (1)	PE20070405A1 (da)
PL (1)	PL1912991T3 (da)
PT (1)	PT1912991E (da)
SI (1)	SI1912991T1 (da)
TW (1)	TW200800217A (da)
WO (2)	WO2007017261A1 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7495005B2 (en) *	2002-08-22	2009-02-24	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, their preparation and their use in pharmaceutical compositions
CN101103030B (zh)	2004-02-14	2010-10-13	史密丝克莱恩比彻姆公司	具有hm74a受体活性的药物
DE102004030502A1 (de)	2004-06-24	2006-01-12	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
BRPI0615145A2 (pt) *	2005-08-10	2009-11-03	Smithkline Beecham Corp	derivados de xantina como agonistas hm74a seletivos
KR20090025262A (ko)	2006-06-23	2009-03-10	인사이트 코포레이션	Ｈｍ７４ａ 아고니스트로서 푸리논 유도체
WO2007150025A2 (en)	2006-06-23	2007-12-27	Incyte Corporation	Purinone derivatives as hm74a agonists
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102007054497B3 (de)	2007-11-13	2009-07-23	Sanofi-Aventis Deutschland Gmbh	Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US9163024B2 (en)	2008-12-08	2015-10-20	Glaxosmithkline Llc	Tris salts of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione
MX2012001729A (es)	2009-08-26	2012-06-13	Sanofi Sa	Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR101799429B1 (ko)	2010-05-03	2017-11-21	에스케이바이오팜 주식회사	신경 세포 사멸 또는 신경 퇴화를 억제하기 위한 약학적 조성물
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en)	2010-06-21	2013-09-10	Sanofi	Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
MX2013001872A (es) *	2010-08-16	2013-09-02	Boehringer Ingelheim Int	Inhibidores de oxadiazol de la produccion de leucotrieno.
WO2012040137A1 (en) *	2010-09-23	2012-03-29	Boehringer Ingelheim International Gmbh	Oxadiazole inhibitors of leukotriene production
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en)	2011-03-08	2014-09-09	Sanofi	Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
SG11201406890YA (en) *	2012-05-30	2014-11-27	Hoffmann La Roche	Triazolo compounds as pde10 inhibitors
CA2899646C (en) *	2013-03-15	2021-08-31	Hydra Biosciences, Inc.	Substituted xanthines and methods of use thereof
CA2911818A1 (en)	2013-05-10	2014-11-13	Nimbus Apollo, Inc.	Acc inhibitors and uses thereof
EA201591959A1 (ru) *	2013-05-10	2016-03-31	Нимбус Аполло, Инк.	Ингибиторы акк и их применение
MX2015015422A (es)	2013-05-10	2016-06-21	Nimbus Apollo Inc	Inhibidores de acetil-coa carboxilasa (acc) y usos de los mismos.
AU2014262547A1 (en)	2013-05-10	2015-11-26	Gilead Apollo, Llc	ACC inhibitors and uses thereof
CN105646492B (zh) *	2014-11-14	2019-04-09	中国医学科学院药物研究所	含五元芳杂环的取代黄嘌呤类化合物及其制备方法和用途
DE102017000359A1 (de)	2016-08-26	2018-03-01	Bihl+Wiedemann Gmbh	Diagnose-Repeater für AS-Interface Netze
WO2018162607A1 (en) *	2017-03-07	2018-09-13	F. Hoffmann-La Roche Ag	Oxadiazole transient receptor potential channel inhibitors
KR102919209B1 (ko)	2018-08-10	2026-01-28	다이아핀 테라퓨틱스, 엘엘씨	트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료
CN112724141A (zh) *	2021-01-21	2021-04-30	南京艾美斐生物医药科技有限公司	一种gpr109a蛋白受体抑制剂及其制备和应用
IL314297A (en) *	2022-02-03	2024-09-01	De Shaw Res Llc	N3-substituted URACIL compounds as TRPA1 inhibitors
EP4658262A1 (en) *	2023-01-30	2025-12-10	D.E. Shaw Research, LLC	Bicyclic imide compounds as trpa1 inhibitors
AR133217A1 (es) *	2023-07-10	2025-09-10	De Shaw Res Llc	Inhibidores de trpa1 bicíclicos y monocíclicos

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2797220A (en) *	1954-12-02	1957-06-25	Univ Michigan	Substituted paraxanthines
GB8906792D0 (en) *	1989-03-23	1989-05-10	Beecham Wuelfing Gmbh & Co Kg	Treatment and compounds
NZ240644A (en)	1990-11-21	1994-08-26	Smithkline Beecham Corp	Use of xanthine derivatives to inhibit the production of tumour necrosis factor (tnf)
WO1993016699A1 (en)	1992-02-21	1993-09-02	Smithkline Beecham Corporation	Tnf inhibitors
DE69332634T2 (de)	1992-03-04	2003-05-08	Cell Therapeutics, Inc.	Enantiomere hydroxylierte xanthinverbindungen
US6693105B1 (en) *	1992-11-16	2004-02-17	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
US6469017B1 (en) *	1998-01-16	2002-10-22	Cell Therapeutics, Inc.	Method of inhibiting interleukin-12 signaling
US5473070A (en) *	1992-11-16	1995-12-05	Cell Therapeutics, Inc.	Substituted long chain alcohol xanthine compounds
US5780476A (en) *	1992-11-16	1998-07-14	Cell Therapeutics, Inc.	Hydroxyl-containing xanthine compounds
IL109161A0 (en)	1993-03-31	1994-06-24	Cell Therapeutics Inc	Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same
US5670506A (en)	1993-04-05	1997-09-23	Cell Therapeutics, Inc.	Halogen, isothiocyanate or azide substituted xanthines
WO1994024133A1 (en)	1993-04-09	1994-10-27	Cell Therapeutics, Inc.	Ring-substituted cell signaling inhibitors
WO1995020589A1 (en)	1994-01-28	1995-08-03	Cell Therapeutics, Inc.	Cell signaling inhibitors
US6878715B1 (en) *	1994-02-18	2005-04-12	Cell Therapeutics, Inc.	Therapeutic compounds for inhibiting interleukin-12 signals and method for using same
WO1995022546A1 (en)	1994-02-18	1995-08-24	Cell Therapeutics, Inc.	Intracellular signalling mediators
US6103730A (en) *	1994-03-24	2000-08-15	Cell Therapeutics, Inc.	Amine substituted compounds
US6780865B1 (en) *	1994-02-18	2004-08-24	Cell Therapeutics, Inc.	Compounds having selective hydrolytic potentials
US5807861A (en) *	1994-03-24	1998-09-15	Cell Therapeutics, Inc.	Amine substituted xanthinyl compounds
US6323201B1 (en) *	1994-12-29	2001-11-27	The Regents Of The University Of California	Compounds for inhibition of ceramide-mediated signal transduction
AR015966A1 (es)	1997-10-17	2001-05-30	Smithkline Beecham Corp	Uso de un compuesto inhibidor de pde4 para la preparacion de un medicamento util para el tratamiento de prurito
AU4205000A (en)	1999-04-09	2000-11-14	Cell Therapeutics, Inc.	Xanthine derivatives and analogs as cell signaling inhibitors
US20030207901A1 (en) *	1999-07-27	2003-11-06	Cell Therapeutics, Inc.	Hydroxyl-containing compounds
US6821978B2 (en) *	2000-09-19	2004-11-23	Schering Corporation	Xanthine phosphodiesterase V inhibitors
US6586429B2 (en) *	2000-11-29	2003-07-01	Cell Therapeutics, Inc.	Tricyclic fused xanthine compounds and their uses
KR100926247B1 (ko) *	2001-02-24	2009-11-12	베링거 잉겔하임 파르마 게엠베하 운트 코 카게	크산틴 유도체를 포함하는 약제학적 조성물 및 이의제조방법
AU2002242910A1 (en)	2001-04-11	2002-10-28	Glaxo Group Limited	Medicaments which are modulators of hm74 and/or hm74a activity
WO2003004496A1 (en) *	2001-07-03	2003-01-16	Novo Nordisk A/S	Dpp-iv-inhibiting purine derivatives for the treatment of diabetes
DE60304911D1 (de)	2002-02-25	2006-06-08	Eisai Co Ltd	Xanthin-Derivate als DPP-IV-Inhibitoren
US7482337B2 (en) *	2002-11-08	2009-01-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CN1227492C (zh) *	2003-03-11	2005-11-16	张跃	一种吸收式空调主体
GB0319124D0 (en) *	2003-08-14	2003-09-17	Smithkline Beecham Corp	Chemical compounds
CN101103030B (zh) *	2004-02-14	2010-10-13	史密丝克莱恩比彻姆公司	具有hm74a受体活性的药物
JP2008517029A (ja) *	2004-10-22	2008-05-22	スミスクライン・ビーチャム・コーポレイション	Ｈｍ７４ａ受容体活性を有するキサンチン誘導体
US20090209561A1 (en) *	2004-10-22	2009-08-20	Richard Jonathan Daniel Hatley	Xanthine Derivatives with HM74A Receptor Activity
WO2006045564A1 (en)	2004-10-22	2006-05-04	Smithkline Beecham Corporation	Xanthine derivatives with hm74a receptor activity
JP2008530074A (ja) *	2005-02-14	2008-08-07	スミスクライン・ビーチャム・コーポレイション	Ｈｍ７４ａ受容体アゴニストとしてのアントラニル酸誘導体
GB0516462D0 (en) *	2005-08-10	2005-09-14	Smithkline Beecham Corp	Novel compounds
BRPI0615145A2 (pt) *	2005-08-10	2009-11-03	Smithkline Beecham Corp	derivados de xantina como agonistas hm74a seletivos
DE102008009758A1 (de) *	2008-02-18	2009-08-20	Beiersdorf Ag	Verwendung von 3-(4-Hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)-propan-1-on zur verbesserten Hautkonturierung bzw. gegen Cellulite
US9163024B2 (en)	2008-12-08	2015-10-20	Glaxosmithkline Llc	Tris salts of 8-chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dione

2006
- 2006-08-08 BR BRPI0615145-0A patent/BRPI0615145A2/pt not_active Application Discontinuation
- 2006-08-08 PL PL06763016T patent/PL1912991T3/pl unknown
- 2006-08-08 PT PT06763016T patent/PT1912991E/pt unknown
- 2006-08-08 US US12/063,432 patent/US20100179128A1/en not_active Abandoned
- 2006-08-08 KR KR1020087005717A patent/KR20080034993A/ko not_active Ceased
- 2006-08-08 DE DE602006018151T patent/DE602006018151D1/de active Active
- 2006-08-08 WO PCT/EP2006/007865 patent/WO2007017261A1/en not_active Ceased
- 2006-08-08 EP EP06776699A patent/EP1912992A1/en not_active Withdrawn
- 2006-08-08 MX MX2008001931A patent/MX2008001931A/es active IP Right Grant
- 2006-08-08 MY MYPI20063833A patent/MY142067A/en unknown
- 2006-08-08 AR ARP060103459A patent/AR055369A1/es unknown
- 2006-08-08 HR HR20100725T patent/HRP20100725T1/hr unknown
- 2006-08-08 PE PE2006000963A patent/PE20070405A1/es not_active Application Discontinuation
- 2006-08-08 AT AT06763016T patent/ATE487719T1/de active
- 2006-08-08 DK DK06763016.0T patent/DK1912991T3/da active
- 2006-08-08 NZ NZ565494A patent/NZ565494A/en not_active IP Right Cessation
- 2006-08-08 EA EA200800555A patent/EA014556B1/ru not_active IP Right Cessation
- 2006-08-08 AU AU2006278215A patent/AU2006278215A1/en not_active Abandoned
- 2006-08-08 JP JP2008525474A patent/JP5112316B2/ja not_active Expired - Fee Related
- 2006-08-08 WO PCT/EP2006/007869 patent/WO2007017262A1/en not_active Ceased
- 2006-08-08 CA CA002626723A patent/CA2626723A1/en not_active Abandoned
- 2006-08-08 EP EP10172674A patent/EP2272848B1/en active Active
- 2006-08-08 SI SI200630916T patent/SI1912991T1/sl unknown
- 2006-08-08 ES ES10172674T patent/ES2401128T3/es active Active
- 2006-08-08 JP JP2008525475A patent/JP2009504592A/ja not_active Withdrawn
- 2006-08-08 US US12/063,434 patent/US8143264B2/en not_active Expired - Fee Related
- 2006-08-08 EP EP06763016A patent/EP1912991B1/en not_active Not-in-force
- 2006-08-08 BR BRPI0614270-2A patent/BRPI0614270A2/pt not_active IP Right Cessation
- 2006-08-08 KR KR1020087005724A patent/KR20080038396A/ko not_active Withdrawn
- 2006-08-08 CA CA002618963A patent/CA2618963A1/en not_active Abandoned
- 2006-08-08 TW TW095128952A patent/TW200800217A/zh unknown
- 2006-08-08 AU AU2006278216A patent/AU2006278216A1/en not_active Abandoned
- 2006-08-08 EA EA200800564A patent/EA200800564A1/ru unknown
- 2006-08-08 MX MX2008001929A patent/MX2008001929A/es not_active Application Discontinuation
2008
- 2008-01-28 IL IL189083A patent/IL189083A0/en unknown
- 2008-01-28 IL IL189081A patent/IL189081A0/en unknown
- 2008-02-08 MA MA30628A patent/MA29692B1/fr unknown
- 2008-02-08 MA MA30629A patent/MA29693B1/fr unknown
- 2008-02-21 CR CR9748A patent/CR9748A/es not_active Application Discontinuation
- 2008-02-21 CR CR9749A patent/CR9749A/es not_active Application Discontinuation
- 2008-03-07 NO NO20081212A patent/NO20081212L/no not_active Application Discontinuation
- 2008-03-07 NO NO20081211A patent/NO20081211L/no not_active Application Discontinuation
2011
- 2011-01-12 CY CY20111100033T patent/CY1111757T1/el unknown
- 2011-04-18 US US13/088,962 patent/US20110257205A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20081211L (no)	2008-05-08
DE602006018151D1 (de)	2010-12-23
PL1912991T3 (pl)	2011-04-29
CA2626723A1 (en)	2007-02-15
WO2007017262A1 (en)	2007-02-15
CR9749A (es)	2008-05-22
EA014556B1 (ru)	2010-12-30
US20110257205A1 (en)	2011-10-20
MX2008001929A (es)	2008-03-24
JP2009504592A (ja)	2009-02-05
CA2618963A1 (en)	2007-02-15
BRPI0615145A2 (pt)	2009-11-03
MA29692B1 (fr)	2008-08-01
SI1912991T1 (sl)	2011-03-31
EP2272848A1 (en)	2011-01-12
AU2006278215A1 (en)	2007-02-15
PE20070405A1 (es)	2007-05-06
CR9748A (es)	2008-05-05
TW200800217A (en)	2008-01-01
EP2272848B1 (en)	2012-12-26
ATE487719T1 (de)	2010-11-15
BRPI0614270A2 (pt)	2011-03-22
CY1111757T1 (el)	2015-10-07
EP1912991A1 (en)	2008-04-23
EP1912991B1 (en)	2010-11-10
HK1116779A1 (en)	2009-01-02
US20100168122A1 (en)	2010-07-01
AR055369A1 (es)	2007-08-22
US8143264B2 (en)	2012-03-27
NZ565494A (en)	2011-06-30
MX2008001931A (es)	2008-03-24
WO2007017261A1 (en)	2007-02-15
HRP20100725T1 (hr)	2011-01-31
IL189083A0 (en)	2008-08-07
ES2401128T3 (es)	2013-04-17
MA29693B1 (fr)	2008-08-01
KR20080038396A (ko)	2008-05-06
NO20081212L (no)	2008-05-06
EA200800555A1 (ru)	2008-08-29
KR20080034993A (ko)	2008-04-22
MY142067A (en)	2010-08-30
JP5112316B2 (ja)	2013-01-09
PT1912991E (pt)	2011-01-17
JP2009504591A (ja)	2009-02-05
AU2006278216A1 (en)	2007-02-15
EP1912992A1 (en)	2008-04-23
US20100179128A1 (en)	2010-07-15
EA200800564A1 (ru)	2008-08-29
IL189081A0 (en)	2008-08-07

Publication	Publication Date	Title
DK1912991T3 (da)	2011-02-21	Xanthinderivater som selektive HM74A-Agonister
NL1031741A1 (nl)	2006-11-07	Purinederivaten.
DK1868999T3 (da)	2009-08-17	Pyridin-3-carboxamidderivater som omvendte CB1-agonister
LTPA2016036I1 (lt)	2017-01-10	Nitrokatechnolio dariniai, kaip COMT inhibitoriai
ATE486874T1 (de)	2010-11-15	Purinonderivate als hm74a-agonisten
NL2000323A1 (nl)	2007-06-21	Pyrimidine-derivaten.
DK2094263T3 (da)	2013-12-02	2-adamantyl-butyramidderivater som selektive 11 beta-hsd1-inhibitorer
DK1789041T3 (da)	2008-09-08	Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
NL2000371A1 (nl)	2007-06-20	Chromaan gesubstitueerde benzimidazoolderivaten.
DK1797042T3 (da)	2009-03-02	Indozolonderivater som 11B-HSD1-inhibitorer
IL195904A0 (en)	2009-09-01	Purinone derivatives as hm74a agonists
DK1846394T3 (da)	2012-01-16	Pyrazolylaminopyridinderivater, der er egnede som kinaseinhibitorer
DK2078001T3 (da)	2010-07-19	Diazepan-acetamidderivater som selektive 11-HSD1-inhibitorer
DK1841768T3 (da)	2009-03-02	Purinderivater virkende som A2A-receptoragonister
NL2000284A1 (nl)	2007-05-07	Pyrazine-derivaten.
ATE487691T1 (de)	2010-11-15	Acetylenderivate
DK1763517T3 (da)	2011-06-06	Pyrimidinderivater som 11beta-HSD1-inhibitorer
DE602006010581D1 (de)	2009-12-31	4-phenyl-6-substituierte pyrimidin-2-carbonitrilderivate
DK1740583T3 (da)	2009-10-19	Oxadiazolon-derivater som ppar-delta-agonister
ZA200800213B (en)	2008-12-31	Benzimidazole derivatives as 5-HT6, 5-HT24
ATE485294T1 (de)	2010-11-15	Azaindol-2-carboxamid-derivate
ATE527255T1 (de)	2011-10-15	Aryl-isoxazol-4-yl-imidazol-derivate
DK1971588T3 (da)	2012-10-22	Tiglien-3-onderivater
IL190012A0 (en)	2009-09-22	Sulphonamide derivatives
ZA200800778B (en)	2008-11-26	Xanthine derivatives as selective HM74A agonists